APAF1 and ovarian cancer: Mir-21 targets apoptotic protease activating factor 1, inhibits ovarian cancer apoptosis, and confers paclitaxel chemoresistance [142], suggesting stromal-derived miR-21 blockade as a potential therapeutic strategy for metastatic and refractory ovarian cancer.